Mind Medicine (MindMed) Inc. Common Shares
MNMD Real Time Price USDRecent trades of MNMD by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MNMD's directors and management
Government lobbying spending instances
-
$15,000 Oct 31, 2024 Issue: Pharmacy
-
$15,000 Oct 31, 2024 Issue: None
-
$15,000 Oct 31, 2024 Issue: None
-
$30,000 Sep 17, 2024 Issue: Health Issues
-
$30,000 Jan 22, 2024 Issue: Health Issues
-
$30,000 Jul 19, 2023 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Formulations of psilocin that have enhanced stability Sep. 24, 2024
-
Patent Title: Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications Jul. 16, 2024
-
Patent Title: Synthesis routes to access mdma prodrugs by using controlled and non-controlled intermediates Feb. 13, 2024
-
Patent Title: 18-mc for treatment of substance use disorders Mar. 07, 2023
-
Patent Title: System and method for patient monitoring of gastrointestinal function using automated stool classifications Dec. 20, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of MNMD in WallStreetBets Daily Discussion
Recent insights relating to MNMD
Recent picks made for MNMD stock on CNBC
ETFs with the largest estimated holdings in MNMD
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MNMD Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.